Exhaled breath profiling in patients with COPD and OSA overlap syndrome: a pilot study
電子鼻技術(shù)用于COPD和OSA重疊綜合征患者呼出氣體分析研究
Silvano Dragonieri, Vitaliano N Quaranta, Pierluigi Carratu, Teresa Ranieri and Onofrio Resta
Department of Respiratory Diseases, University of Bari, Piazza Giulio Cesare 11,Bari, Italy
: silvano.dragonieri@uniba.it
Keywords: exhaled breath, volatile organic compounds, electronic nose, OSA, COPD, overlap syndrome
Abstract
The analysis of volatile organic compounds (VOCs) by an electronic nose (Cyranose 320) is a groundbreaking method that provides distinct exhaled molecular patterns in several respiratory and systemic diseases. It has been shown that an e-nose can detect obstructive sleep apnea (OSA) as well as chronic obstructive pulmonary disease (COPD). OSA and COPD are sometimes associated into the so-called overlap syndrome (OVS). In this pilot study we hypothesized that an e-nose could
discriminate the exhaled breath of patients with OVS from that of subjects with OSA and COPD alone. Thirteen patients with OSA, 15 patients with COPD and 13 with OVS participated in a crosssectional study. Exhaled breath was collected by a formerly validated method and sampled by using an electronic nose (Cyranose 320). Raw data were analyzed by canonical discriminant analysis on principal component reduction. Cross-validation accuracy (CVA) and ROC-curves were calculated.
External validation in newly recruited patients (6 OSA, 6 OVS and 6 COPD) was tested using the previous training set. Breathprints of patients with OSA clustered distinctly from those with OVS (CVA = 96.2%) as well as those with COPD (CVA = 82.1%). Breathprints from OVS were not significantly separated from those of COPD (CVA = 67.9%). External validation confirmed the above findings. The e-nose can distinguish with high accuracy the exhaled VOC-profile of patients with OSA from those with OVS as well as those with COPD. This warrants future studies to confirm the potential of this technique in the non-invasive detection of sleep apnea.
用電子鼻(Cyranose320)分析揮發(fā)性有機(jī)化合物(VOCs)是一種突破性的方法，可在多種呼吸系統(tǒng)疾病中提供不同的呼出分子模式。研究表明，電子鼻可以檢測(cè)阻塞性睡眠呼吸暫停(OSA)和慢性阻塞性肺疾病(COPD)。OSA和慢性阻塞性肺病有時(shí)與所謂的重疊綜合征(OVS)有關(guān)。在這項(xiàng)初步研究中，我們假設(shè)電子鼻可以區(qū)分OVS患者的呼氣與OSA和COPD患者的呼氣。13例OSA患者、15例COPD患者和13例OVS患者參與了一項(xiàng)橫斷面研究。通過(guò)先前驗(yàn)證的方法收集呼出的呼吸，并使用電子鼻(Cyranose320)取樣。對(duì)原始數(shù)據(jù)進(jìn)行主成分約簡(jiǎn)的典型判別分析。計(jì)算了交叉驗(yàn)證精度(CVA)和ROC曲線。
在新招募的患者(6例OSA，6例OVS和6例COPD)中，使用先前的訓(xùn)練集對(duì)外部驗(yàn)證進(jìn)行測(cè)試。OSA患者的呼吸圖與OVS患者(CVA=96.2%)和COPD患者(CVA=82.1%)明顯聚集。卵母細(xì)胞的呼吸印痕與慢性阻塞性肺病的呼吸印痕沒(méi)有明顯的分離(cva=67.9%)。外部驗(yàn)證證實(shí)了上述發(fā)現(xiàn)。電子鼻可以很準(zhǔn)確地區(qū)分OSA患者和OVS患者以及慢性阻塞性肺病患者呼出的VOC特征。這就需要未來(lái)的研究來(lái)證實(shí)這種技術(shù)在無(wú)創(chuàng)檢測(cè)睡眠呼吸暫停中的潛力。
會(huì)員1.png)
